[Continuous intravenous infusion of insulin to girls with hereditary tall growth and secretion of human growth hormone, prior to and during Deposiston treatment (author's transl)].
Continuous intravenous insulin infusion tests, accompanied by growth hormone determination, were applied to 40 girls of tall growth whose final lengths were predicted to be in excess of 181 cm. The girls were aged between nine and half and 14 years and one month, all of them being in the premenarchic phase. The tests were conducted prior to and following at least one year of Deposiston therapy (oestrogen/gestagen). - Really effective inhibition of growth (7.4 +/- 0.6 cm) was obtained only from five girls, aged between nine years and ten months and eleven years, in whom basal secretion of HGH was lower with significance than that of the whole group, with their stimulation reaction being fully retained. Secretion of somatotropic hormone (STH) of the other girls remained unaffected, prior to and following treatment. The weekly oestrogen dose of 1 mg was relatively low, when compared to propositions made by other authors, but it seemed to be justified by the average reduction in expected final body length obtained for the probands reviewed (5.4 +/- 2.0 cm).
D000293:Adolescent; D001827:Body Height; D002648:Child; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage; D004338:Drug Combinations; D004997:Ethinyl Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D006130:Growth Disorders / Q000188:drug therapy* / Q000503:physiopathology; D013006:Growth Hormone / Q000378:metabolism; D006801:Humans; D007263:Infusions, Parenteral; D007328:Insulin / Q000008:administration & dosage*; D009640:Norethindrone / Q000008:administration & dosage*
D003277:Contraceptives, Oral, Combined; D004338:Drug Combinations; D007328:Insulin; D004997:Ethinyl Estradiol; C011436:Deposiston; D013006:Growth Hormone; D009640:Norethindrone
Intravenöser Insulinbelastungstest und Wachsdtumshormonsekretion bei Mädchen mit konstitutionell-hereditärem Hochwuchs vor und während der Behandlung mit Deposiston.